Tunis Sean, Whicher Danielle
Center for Medical Technology Policy, Baltimore, Maryland 21202, USA.
J Am Coll Radiol. 2009 May;6(5):360-5. doi: 10.1016/j.jacr.2009.01.016.
The National Oncologic PET Registry (NOPR) was one of the first attempts of the Centers for Medicare & Medicaid Services (CMS) at coverage with evidence development. Under this coverage policy, the agency will provide payment for a technology only if patients and providers agree to enroll in a prospective study or registry. The NOPR was designed to determine if the results of positron emission tomography scans influence physicians' intended plans of patient management while imposing minimal restrictions on the use of such scans in the clinical setting. The experience of policymakers, methodologists, physicians, and patients with the NOPR provides some useful insights into the utility and challenges of implementing, financing, and creating a robust methodology for coverage with evidence development in the future. Moving to a system of evidence-based medical technology diffusion will require all health care decision makers to become involved in evidence generation and reach an agreement about the type of evidence required to make informed medical decisions.
国家肿瘤PET登记处(NOPR)是医疗保险和医疗补助服务中心(CMS)最早尝试的基于证据开展覆盖范围评估的项目之一。根据这项覆盖范围政策,只有患者和医疗服务提供者同意参与一项前瞻性研究或登记处项目,该机构才会为一项技术提供支付。NOPR旨在确定正电子发射断层扫描的结果是否会影响医生对患者管理的预期计划,同时在临床环境中对此类扫描的使用施加最小限制。政策制定者、方法学家、医生和患者在NOPR方面的经验为未来实施、资助和创建一个强大的基于证据开展覆盖范围评估的方法提供了一些有用的见解。转向基于证据的医疗技术传播系统将要求所有医疗保健决策者参与证据生成,并就做出明智医疗决策所需的证据类型达成一致。